All articles by Abigail Beaney

Abigail Beaney is a healthcare reporter for the Clinical Trials Arena. Coming from a journalistic background Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Based in Manchester, Abigail has previously worked in local news and has interests in research into the treatment and prevention of cancer, heart disease and dementia.

Abigail Beaney

Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’

CEO of H1 Ariel Katz’s mission is ‘to connect the world to the right doctor’ with a focus on connecting sponsors with the right PIs.

Another blow for Gilead after third magrolimab hit, upsetting $4.9bn deal

The drug, acquired in 2020 as part of a $4.9b deal, is ‘unlikely to demonstrate survival benefit compared to standard of care’ in acute myeloid leukaemia.

Second success for Alto Neuroscience in AI-developed brain drug

Alto Neurosciences has announced the results of its Phase IIa study of its pipeline candidate Alto-100 from the PTSD patient cohort.

Dual primary endpoints met in Phase III trial of Padcev and Keytruda

The results of Seagen and Astellas’ Phase III trial of Padcev and Keytruda will be presented during an upcoming medical meeting.

Will there ever be a cure for Alzheimer’s disease?

As the population ages, Alzheimer’s disease is more prevalent. Will treatment ever be effective enough or will prevention be key?

Bucking the trend: How the UK can replicate the Greater Manchester model

Commercial clinical trial initiation has decreased over the past five years in the UK however, Greater Manchester has bucked the trend.

Concerns raised as FDA approves Covid vaccines without clinical trials

A number of people have raised concerns the FDA has approved one vaccine without clinical trial data however this is not uncommon.

Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients

Mirati reported that 31% of Krazati patients with previously treated KRASG12C-mutated NSCLC demonstrated overall survival of two years.

‘UK commercial clinical trials will double and double again’ – Lord James O’Shaughnessy

Lord James O’Shaughnessy talks to the Clinical Trials Arena team about his review of commercial clinical trials in the UK and the path the country can take to recovery.

Hope for the UK clinical trial landscape but it requires a lot of work

The Arena International Outsourcing in Clinical Trials UK and Ireland discussed how the UK’s clinical trial landscape has taken a hit and what improvements are needed to make it a more viable country for research.